Beverly Moy
@beverlymoy
Medical Oncologist, Director of Cancer Equity & Clinical Director of Breast Oncology at Mass General Hospital; Professor, Harvard Medical School. Views my own.
ID: 1463076127
27-05-2013 20:19:42
495 Tweet
1,1K Followers
288 Following
Kevin Kalinsky, MD, MS, FASCO presents postMONARCH, the first trial showing benefit of continuing CDK4/6 inhibition after progression on prior CDK. Congrats to investigators, including senior author Mass General Cancer Center MGH Breast Oncology Seth Wander #ASCO24